Diabetes is a disease that occurs when your blood glucose, also called blood sugar, is too high. Blood glucose is your main source of energy and comes from the food you eat. Diabetes is a chronic disease that occurs when the pancreas is no longer able to make insulin, or when the body cannot make good use of the insulin it produces. Insulin is a hormone made by the pancreas, helps glucose from food get into your cells to be used for energy. Sometimes your body doesn’t make enough—or any—insulin or doesn’t use insulin well. Glucose then stays in your blood and doesn’t reach your cells. There are three main types of diabetes – type 1, type 2 and gestational.
The term diabetes is collectively considered as a bunch, rather than a single disease, of situations related to abnormal increase in the blood glucose level attributed to the absence/inactivity/resistance of the hormone insulin. Literally, it can affect people between ‘8 to 80’s depending on its type and auxiliary factors like age, lifestyle, food habit (‘obesity’), heredity, ethnicity etc. As of 2019, around 463 million people of adult age group (20-79 years) worldwide had been affected by diabetes with estimate of annual global expenditure of USD 760 billion, about 12% of total global health expenses. An escalation of this number of affected adults rising up to 700 million by 2045 is predicted by the renowned sources like International Diabetes Federation, WHO, Centre for Disease Control etc. Despite these alarming statistics, 50-80% (varying between countries) of people with diabetes are found unaware of their ailment. Eventually, most individuals are diagnosed with the condition ‘accidentally’, either undergoing some preoperative investigation or other routine test. That makes diabetes a ‘Silent Killer’, an insidiously expanding potent public health threat.
Why I3T Focuses on that:
At I3TK, we aim to address this burning issue by development of novel therapeutic intervention ameliorating diabetic consequences. Pathophysiological models will be established in vitro and in vivo, and efficacy of the innovative strategies will be investigated. ‘Low-and-Middle-Income-Group’ (LMIG) population has been reported to be most severally impacted by Diabetes. Most of the Indian population resides into this group. We set our focus to develop cost-effective measures to counter this metabolic syndrome leading to reduction of a huge societal health burden.